NCT05652660View on ClinicalTrials.gov

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 9, 2022

Primary Completion Date

February 9, 2023

Study Completion Date

March 6, 2023

Conditions
Healthy
Interventions
DRUG

ARV-471

Experimental

DRUG

Rosuvastatin

Probe substrate

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05652660 - A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults | Biotech Hunter | Biotech Hunter